中国当代医药Issue(18)：91-93,3.
唑来膦酸预防来曲唑治疗绝经后乳腺癌患者骨质流失的效果观察
Effect observation of zoledronic acid combined with letrozole treating bone loss in post-menopausal patients with breast cancer
连志标 1方志潮 1李幸运 1黄少辉 1吴泽炀1
作者信息
- 1. 广东省潮州市人民医院放射科，广东潮州 521011
- 折叠
摘要
Abstract
Objective To explore the effect of zoledronic acid combined with letrozole treating bone loss in post-menopausal patients with breast cancer. Methods From November 2009 to December 2011,120 patients with breast cancer with stable disease condition and positive hormone receptor after menopause admitted into our hospital were se-lected as research objects.They were evenly divided into observation group and control group in random.In observation group,oral administration of letrozole combined with intravenous infusion of zoledronic acid was provided,while in con-trol group,only letrozole was used orally.Bone density of lumbar vertebra was determined once per year,and observed for 2 years.The change of bone density and adverse reaction of patients in two groups was observed respectively. Results In observation group,there were 24 cases (40.00%) occurred with osteoporosis,while in control group,the number was 51 (85.00%) after 2 years treatment which displayed a statistical difference (P<0.05).There were 9 cases (15.00%) occur-ring with adverse reaction (transient fever in 5 cases and ostealgia in 4 cases),and the degree was grade Ⅰ,which were alleviated by certain symptomatic treatment and had no significant influence on patients. Conclusion Intravenous infu-sion of zoledronic acid every 3 months plays an obvious clinical application value on prevention of bone loss in en-docrine treatment for patients with post-menopausal breast cancer,and can greatly improve patient's quality of life, which is applicable to clinical expansion and application.关键词
唑来膦酸/来曲唑/乳腺癌/骨质流失Key words
Zoledronic acid/Letrozole/Breast cancer/Bone loss分类
医药卫生引用本文复制引用
连志标,方志潮,李幸运,黄少辉,吴泽炀..唑来膦酸预防来曲唑治疗绝经后乳腺癌患者骨质流失的效果观察[J].中国当代医药,2015,(18):91-93,3.
